Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 275

1.

Hybrid models identified a 12-gene signature for lung cancer prognosis and chemoresponse prediction.

Wan YW, Sabbagh E, Raese R, Qian Y, Luo D, Denvir J, Vallyathan V, Castranova V, Guo NL.

PLoS One. 2010 Aug 17;5(8):e12222. doi: 10.1371/journal.pone.0012222.

2.

Signaling pathway-based identification of extensive prognostic gene signatures for lung adenocarcinoma.

Wan YW, Beer DG, Guo NL.

Lung Cancer. 2012 Apr;76(1):98-105. doi: 10.1016/j.lungcan.2011.09.016. Epub 2011 Nov 1.

3.

Pathway-based identification of a smoking associated 6-gene signature predictive of lung cancer risk and survival.

Guo NL, Wan YW.

Artif Intell Med. 2012 Jun;55(2):97-105. doi: 10.1016/j.artmed.2012.01.001. Epub 2012 Feb 11.

4.

Confirmation of gene expression-based prediction of survival in non-small cell lung cancer.

Guo NL, Wan YW, Tosun K, Lin H, Msiska Z, Flynn DC, Remick SC, Vallyathan V, Dowlati A, Shi X, Castranova V, Beer DG, Qian Y.

Clin Cancer Res. 2008 Dec 15;14(24):8213-20. doi: 10.1158/1078-0432.CCR-08-0095.

5.

Genome-wide analysis of three-way interplay among gene expression, cancer cell invasion and anti-cancer compound sensitivity.

Hsu YC, Chen HY, Yuan S, Yu SL, Lin CH, Wu G, Yang PC, Li KC.

BMC Med. 2013 Apr 16;11:106. doi: 10.1186/1741-7015-11-106.

6.

Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer.

Zhu CQ, Ding K, Strumpf D, Weir BA, Meyerson M, Pennell N, Thomas RK, Naoki K, Ladd-Acosta C, Liu N, Pintilie M, Der S, Seymour L, Jurisica I, Shepherd FA, Tsao MS.

J Clin Oncol. 2010 Oct 10;28(29):4417-24. doi: 10.1200/JCO.2009.26.4325. Epub 2010 Sep 7. Erratum in: J Clin Oncol. 2010 Dec 1;28(34):5126. J Clin Oncol. 2014 Feb 1;32(4):365.

7.

Gene expression signature predicts recurrence in lung adenocarcinoma.

Larsen JE, Pavey SJ, Passmore LH, Bowman RV, Hayward NK, Fong KM.

Clin Cancer Res. 2007 May 15;13(10):2946-54.

8.

A population-based gene signature is predictive of breast cancer survival and chemoresponse.

Rathnagiriswaran S, Wan YW, Abraham J, Castranova V, Qian Y, Guo NL.

Int J Oncol. 2010 Mar;36(3):607-16.

9.

Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non-Small Cell Lung Cancer.

Li B, Cui Y, Diehn M, Li R.

JAMA Oncol. 2017 Nov 1;3(11):1529-1537. doi: 10.1001/jamaoncol.2017.1609.

PMID:
28687838
10.

Gene-expression signature predicts postoperative recurrence in stage I non-small cell lung cancer patients.

Lu Y, Wang L, Liu P, Yang P, You M.

PLoS One. 2012;7(1):e30880. doi: 10.1371/journal.pone.0030880. Epub 2012 Jan 23.

11.

Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung.

Raponi M, Zhang Y, Yu J, Chen G, Lee G, Taylor JM, Macdonald J, Thomas D, Moskaluk C, Wang Y, Beer DG.

Cancer Res. 2006 Aug 1;66(15):7466-72.

12.

Validation of a histology-independent prognostic gene signature for early-stage, non-small-cell lung cancer including stage IA patients.

Der SD, Sykes J, Pintilie M, Zhu CQ, Strumpf D, Liu N, Jurisica I, Shepherd FA, Tsao MS.

J Thorac Oncol. 2014 Jan;9(1):59-64. doi: 10.1097/JTO.0000000000000042.

13.

Stratification of resectable lung adenocarcinoma by molecular and pathological risk estimators.

Rakha E, Pajares MJ, Ilie M, Pio R, Echeveste J, Hughes E, Soomro I, Long E, Idoate MA, Wagner S, Lanchbury JS, Baldwin DR, Hofman P, Montuenga LM.

Eur J Cancer. 2015 Sep;51(14):1897-903. doi: 10.1016/j.ejca.2015.07.015. Epub 2015 Jul 30.

PMID:
26235745
14.

A Cost-Effectiveness Analysis of Using the JBR.10-Based 15-Gene Expression Signature to Guide Adjuvant Chemotherapy in Early Stage Non-Small-Cell Lung Cancer.

Wong KM, Ding K, Li S, Bradbury P, Tsao MS, Der SD, Shepherd FA, Chung C, Ng R, Seymour L, Leighl NB.

Clin Lung Cancer. 2017 Jan;18(1):e41-e47. doi: 10.1016/j.cllc.2016.06.009. Epub 2016 Jul 9.

PMID:
27502323
15.
16.

Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).

Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V, Chao TY, Nakagawa K, Chu DT, Saijo N, Duffield EL, Rukazenkov Y, Speake G, Jiang H, Armour AA, To KF, Yang JC, Mok TS.

J Clin Oncol. 2011 Jul 20;29(21):2866-74. doi: 10.1200/JCO.2010.33.4235. Epub 2011 Jun 13.

PMID:
21670455
17.

Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer.

Acharya CR, Hsu DS, Anders CK, Anguiano A, Salter KH, Walters KS, Redman RC, Tuchman SA, Moylan CA, Mukherjee S, Barry WT, Dressman HK, Ginsburg GS, Marcom KP, Garman KS, Lyman GH, Nevins JR, Potti A.

JAMA. 2008 Apr 2;299(13):1574-87. doi: 10.1001/jama.299.13.1574. Retraction in: Acharya CR, Hsu DS, Anders CK, Anguiano A, Salter KH, Walters KS, Redman RC, Tuchman SA, Moylan CA, Mukherjee S, Barry WT, Dressman HK, Ginsburg GS, Marcom KP, Garman KS, Lyman GH, Nevins JR, Potti A. JAMA. 2012 Feb 1;307(5):453.

PMID:
18387932
18.

Prognostic and predictive value of a malignancy-risk gene signature in early-stage non-small cell lung cancer.

Chen DT, Hsu YL, Fulp WJ, Coppola D, Haura EB, Yeatman TJ, Cress WD.

J Natl Cancer Inst. 2011 Dec 21;103(24):1859-70. doi: 10.1093/jnci/djr420. Epub 2011 Dec 8.

19.
20.

Use of a cytokine gene expression signature in lung adenocarcinoma and the surrounding tissue as a prognostic classifier.

Seike M, Yanaihara N, Bowman ED, Zanetti KA, Budhu A, Kumamoto K, Mechanic LE, Matsumoto S, Yokota J, Shibata T, Sugimura H, Gemma A, Kudoh S, Wang XW, Harris CC.

J Natl Cancer Inst. 2007 Aug 15;99(16):1257-69. Epub 2007 Aug 8.

PMID:
17686824

Supplemental Content

Support Center